<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neth Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Neth Heart J</journal-id><journal-title-group><journal-title>Netherlands Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">1568-5888</issn><issn pub-type="epub">1876-6250</issn><publisher><publisher-name>BSL Media &#x00026; Learning</publisher-name><publisher-loc>Houten</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40402394</article-id><article-id pub-id-type="pmc">PMC12098239</article-id>
<article-id pub-id-type="publisher-id">1965</article-id><article-id pub-id-type="doi">10.1007/s12471-025-01965-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Studies on ICD guidelines, cardiac amyloidosis in HFpEF, and remote monitoring outcomes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>van der Harst</surname><given-names>Pim</given-names></name><address><email>p.vanderharst@umcutrecht.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0575yy874</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9012 6352</institution-id><institution>Department of Cardiology, Division of Heart and Lungs, </institution><institution>University Medical Centre Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>33</volume><issue>6</issue><fpage>183</fpage><lpage>183</lpage><history><date date-type="accepted"><day>30</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Society of Nederlandse Vereniging voor Cardiologie (NVVC) and Springer Media B.V. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>This issue of the <italic>Netherlands Heart Journal</italic>, presents three original studies with valuable insights into evolving clinical practice in electrophysiology and heart failure care.</p><p>Evertz et&#x000a0;al. report on the impact of the 2023 Dutch guideline for primary prevention ICD implantation in patients with non-ischaemic cardiomyopathy (NICMP) [<xref ref-type="bibr" rid="CR1">1</xref>]. Their single-centre analysis shows the new criteria significantly reduce ICD implantations, but many &#x02018;de-selected&#x02019; patients still received appropriate ICD therapies, highlighting the ongoing tension between patient selection and undertreatment, a&#x000a0;challenge requiring further research.</p><p>Achten et&#x000a0;al. present a&#x000a0;systematic screening study of transthyretin amyloid cardiomyopathy (ATTR-CM) in an unselected heart failure with preserved ejection fraction (HFpEF) cohort [<xref ref-type="bibr" rid="CR2">2</xref>]. They report a 3% prevalence, but find that one-third of diagnosed patients had no increased left ventricular wall thickness at diagnosis. These results highlight the risk of overreliance on wall thickness alone for ATTR-CM detection, emphasise the need for broader clinical awareness and possibly more refined screening strategies.</p><p>The HERO study by Adriaansen et&#x000a0;al. evaluates remote monitoring (RM) in pacemaker patients at elevated stroke risk without prior atrial fibrillation [<xref ref-type="bibr" rid="CR3">3</xref>]. Although the HERO registry shows high RM acceptance and substantial arrhythmia burden, it did not significantly improve time to arrhythmia detection vs. conventional care. These findings highlight considerations for RM integration into clinical workflows and suggest opportunities for smarter, more efficient remote care, potentially enhanced by artificial intelligence.</p><p>These studies highlight challenges and opportunities in cardiovascular care: refining indications using real-world data, detecting disease earlier, and meaningful use of technological innovations. Careful interpretation and focus on individual patient care remain essential as clinical practice evolves.</p><p>I&#x000a0;hope you find these contributions both informative and inspiring for your practice.</p></body><back><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p>P.&#x000a0;van der Harst declares that he has no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Evertz</surname><given-names>R</given-names></name><name><surname>Beukema</surname><given-names>R</given-names></name><name><surname>Westra</surname><given-names>S</given-names></name><etal/></person-group><article-title>Primary prevention ICD in non-ischaemic cardiomyopathy: an ongoing search for improvement of current indications</article-title><source>Neth Heart J</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s12471-025-01960-5</pub-id><pub-id pub-id-type="pmid">40354022</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Evertz&#x000a0;R, et&#x000a0;al. Primary prevention ICD in non-ischaemic cardiomyopathy: an ongoing search for improvement of current indications. Neth Heart&#x000a0;J. 2025; 10.1007/s12471-025-01960-5.<pub-id pub-id-type="pmid">40354022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Achten</surname><given-names>A</given-names></name><name><surname>van Empel</surname><given-names>VPM</given-names></name><name><surname>Weerts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevalence of transthyretin amyloid cardiomyopathy in an unselected cohort with heart failure with preserved ejection fraction</article-title><source>Neth Heart J</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s12471-025-01954-3</pub-id><pub-id pub-id-type="pmid">40293703</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Achten&#x000a0;A, et&#x000a0;al. Prevalence of transthyretin amyloid cardiomyopathy in an unselected cohort with heart failure with preserved ejection fraction. Neth Heart&#x000a0;J. 2025; 10.1007/s12471-025-01954-3.<pub-id pub-id-type="pmid">40293703</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Adriaansen</surname><given-names>FW</given-names></name><name><surname>Seelig</surname><given-names>J</given-names></name><name><surname>de Vries</surname><given-names>TAC</given-names></name><etal/></person-group><article-title>Heart rhythm management optimisation of pacemaker recipients using remote monitoring: the HERO registry</article-title><source>Neth Heart J</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s12471-025-01953-4</pub-id><pub-id pub-id-type="pmid">40343620</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Adriaansen&#x000a0;FW, et&#x000a0;al. Heart rhythm management optimisation of pacemaker recipients using remote monitoring: the HERO registry. Neth Heart&#x000a0;J. 2025; 10.1007/s12471-025-01953-4.<pub-id pub-id-type="pmid">40343620</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>